REALTROMINS, Inc (Chapel Hill, NC USA) created an advanced Predictive Analytic for Healthcare (PICU REALTROMINS) which continuously assesses the risk of mortality in critically ill children (PCT International Application No PCT/US2007/012736) (published 3/10)
Two additional medical devices have been created with our technologies to assess: 1)critically ill newborns in the Neonatal ICU (Neonatal REALTROMINS); and 2)hospitalized children outside the ICU (Pediatric Rapid Response REALTROMINS) (PCT/US2011/42416 (6/11)).
Our research team is continuing to develop additional devices for use in:
1)critically ill adults (Adult REALTROMINS); 2)hospitalized adults (Adult Rapid Response REALTROMINS); and 3)wounded combatants and disaster victims (Triage REALTROMINS).
The most important function of a pediatric intensive care unit (PICU) is to provide advanced computerized monitoring capabilities to clinicians to evaluate the clinical status of patients and to track their response to a wide range of interventions. We have integrated multiple classes of variables, such as:
A. continuous physiologic signals;
B. advanced measures of variability;
C. laboratory measures of organ function;
D. advanced measure of variability of (C);
E. demographic & diagnosis related predictors;
and analyzed them with advanced signal processing, statistical, and neural network techniques to create a real time, continuously updated, risk for mortality score in critically ill children. REALTROMINS (REAL Time Risk of Mortality and INStability) is a new advanced technology to be used by physicians to guide critically ill children back to health. REALTROMINS is being commercialized to the ICU monitoring industry (valued at $1.2 billion of sales annually) with the assistance of the 1) Office of Technology Development and 2) Carolina Entrepreneur’s Initiative at the Kenan-Flagler School of Business, both at the University of North Carolina.